Mariana Brait

Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer.

Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer.

Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer.

Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression.

Association between lifestyle factors and CpG island methylation in a cancer-free population.

KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses.

Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer.

DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation.

Cancer epigenetics: above and beyond.

AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.

Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer.

Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer.

Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers.

Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma.

Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.

Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population.

GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.

The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.

Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine.

An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine.

Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile.

Notch1 mutations are drivers of oral tumorigenesis.

Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.

Calcium calmodulin dependent kinase kinase 2 - a novel therapeutic target for gastric adenocarcinoma.

Epigenetic silencing of S100A2 in bladder and head and neck cancers.

Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA.

High-performance detection of somatic D-loop mutation in urothelial cell carcinoma patients by polymorphism ratio sequencing.

Comparative mutational landscape analysis of patient-derived tumour xenografts.

Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients.

Expression of GULP1 in bronchial epithelium is associated with the progression of emphysema in chronic obstructive pulmonary disease.

MGMT and CALCA promoter methylation are associated with poor prognosis in testicular germ cell tumor patients.

Advancing toward a molecular characterization of polymorphous low grade adenocarcinoma.

Tobacco and alcohol-induced epigenetic changes in oral carcinoma.

Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1.

Tissue and Cell-Free DNA-Based Epigenomic Approaches for Cancer Detection.

Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma.

GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma.

Clinical and Prognostic Significance of the Eighth Edition Oral Cancer Staging System.

High-risk HPV infection-associated hypermethylated genes in oropharyngeal squamous cell carcinomas.